Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus

APS. Hungin, CR. Mitchell, P. Whorwell, C. Mulligan, O. Cole, L. Agréus, P. Fracasso, C. Lionis, J. Mendive, JM. Philippart de Foy, B. Seifert, KA. Wensaas, C. Winchester, N. de Wit, European Society for Primary Care Gastroenterology,

. 2018 ; 47 (8) : 1054-1070. [pub] 20180220

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Systematic Review

E-resources Online Full text

NLK Free Medical Journals from 1997 to 18 months ago
Medline Complete (EBSCOhost) from 1998-01-01 to 1 year ago
Wiley Free Content from 1997 to 18 months ago

BACKGROUND: In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. AIM: To update the consensus with new evidence. METHODS: A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previously developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. RESULTS: A total of 70 studies were included (IBS, 34; diarrhoea associated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and "high" evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotics or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and "moderate" evidence indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. CONCLUSIONS: This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publications did not report benefits of probiotics, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028565
003      
CZ-PrNML
005      
20190816095537.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/apt.14539 $2 doi
035    __
$a (PubMed)29460487
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hungin, A P S $u Newcastle upon Tyne, UK.
245    10
$a Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus / $c APS. Hungin, CR. Mitchell, P. Whorwell, C. Mulligan, O. Cole, L. Agréus, P. Fracasso, C. Lionis, J. Mendive, JM. Philippart de Foy, B. Seifert, KA. Wensaas, C. Winchester, N. de Wit, European Society for Primary Care Gastroenterology,
520    9_
$a BACKGROUND: In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. AIM: To update the consensus with new evidence. METHODS: A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previously developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. RESULTS: A total of 70 studies were included (IBS, 34; diarrhoea associated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and "high" evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotics or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and "moderate" evidence indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. CONCLUSIONS: This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publications did not report benefits of probiotics, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.
650    _2
$a zvířata $7 D000818
650    _2
$a konsensus $7 D032921
650    _2
$a průjem $x farmakoterapie $7 D003967
650    _2
$a infekce vyvolané Helicobacter pylori $x farmakoterapie $7 D016481
650    12
$a Helicobacter pylori $7 D016480
650    _2
$a lidé $7 D006801
650    _2
$a syndrom dráždivého tračníku $x farmakoterapie $7 D043183
650    _2
$a probiotika $x terapeutické užití $7 D019936
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Mitchell, C R $u Oxford, UK.
700    1_
$a Whorwell, P $u Manchester, UK.
700    1_
$a Mulligan, C $u Brighton, UK.
700    1_
$a Cole, O $u Oxford, UK.
700    1_
$a Agréus, L $u Stockholm, Sweden.
700    1_
$a Fracasso, P $u Rome, Italy.
700    1_
$a Lionis, C $u Heraklion, Greece.
700    1_
$a Mendive, J $u Barcelona, Spain.
700    1_
$a Philippart de Foy, J-M $u Brussels, Belgium.
700    1_
$a Seifert, B $u Prague, Czech Republic.
700    1_
$a Wensaas, K-A $u Bergen, Norway.
700    1_
$a Winchester, C $u Oxford, UK.
700    1_
$a de Wit, N $u Utrecht, The Netherlands.
710    2_
$a European Society for Primary Care Gastroenterology
773    0_
$w MED00009085 $t Alimentary pharmacology & therapeutics $x 1365-2036 $g Roč. 47, č. 8 (2018), s. 1054-1070
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29460487 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190816095807 $b ABA008
999    __
$a ok $b bmc $g 1433714 $s 1067025
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 47 $c 8 $d 1054-1070 $e 20180220 $i 1365-2036 $m Alimentary pharmacology & therapeutics $n Aliment Pharmacol Ther $x MED00009085
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...